danafarberbostonchildrens.org
Jun 23, 2025, 11:22
Riten Kumar Shared New ISTH Data: 3-Month Apixaban Course Shows Better Safety Profile Than Rivaroxaban in Acute VTE
Riten Kumar, Associate Professor of Pediatrics at Harvard, posted on X:
“Late breaking abstract at isth – 3 months of apixaban is safer than rivaroxaban for management of acute VTE!!!”
Be updated with Hemostasis Today.
-
Jul 17, 2026, 10:12Julien Perrin: Presenting Thalassemia Coagulation Research at ISTH 2026
-
Jul 17, 2026, 10:08Cihan Ay: Thank you for making ISTH 2026 such a remarkable congress
-
Jul 17, 2026, 10:06Laura Cunliffe: That Is a Wrap for Meg and Me at ISTH 2026 in Paris
-
Jul 17, 2026, 10:03Roberta Gualtierotti: Updating on the Standardization of ultrasound definitions in hemophilic arthropathy at the ISTH 2026
-
Jul 17, 2026, 09:57Hrushikesh Vyas – A Wonderful Week Presenting Inherited Thrombocytopenia Research at ISTH 2026
-
Jul 17, 2026, 09:42Samin Mohsenian: Proud to Receive a Top Poster Award at ISTH 2026
-
Jul 17, 2026, 09:36Wolfgang Miesbach: A Landmark Case of Supratherapeutic FIX Following Gene Therapy Presented at ISTH 2026
-
Jul 17, 2026, 09:28Lisa Astorga: Leaving ISTH 2026 Inspired by the Global Thrombosis and Hemostasis Community
-
Jul 17, 2026, 09:23Maxime Dely: Honored to Reach My 6th Plasma Donation of 2026